Uppgifter
Kategori: Nyheter
Dear Colleagues,
 
We are delighted to present to you the congress highlights at diabetes-symposium.org.
 
 
Editorial Office
Sciarc
 
Nyhetsinfo
www red DiabetologNytt
Uppgifter
Träffar: 2223

Uppgifter
Kategori: Nyheter
Sverige behåller andraplatsen i global innovationsrankning
 
De fem nordiska länderna finns bland de 25 högst rankade länderna i Global Innovation Index 2017,

Sverige behåller sin position som världens näst mest innovativa land, enligt Global Innovation Index 2017,
 
Schweiz är för sjätte året i rad det mest
...
Uppgifter
Träffar: 2189

Uppgifter
Kategori: Nyheter
Ingen utvärdering av FreeStyle Libre
 
Nedan är utlagt på TLVs www
 
TLV har inte möjlighet att publicera en hälsoekonomisk utvärdering av den kontinuerliga glukosmätaren FreeStyle Libre, eftersom företaget som marknadsför produkten valt att inte bidra med nödvändigt underlag.
 
I dag använder minst 27.000
...
Uppgifter
Träffar: 2258

Uppgifter
Kategori: Nyheter
DEVOTE: Tresiba as Safe as Glargine With Less Severe Hypoglycemia
 
SAN DIEGO — For the treatment of type 2 diabetes, the ultra-long–acting, once-daily basal insulin degludec (Tresiba, Novo Nordisk) is as safe in cardiovascular terms as insulin glargine and is associated with much lower rates of
...
Uppgifter
Träffar: 2486

Uppgifter
Kategori: Nyheter
 
SAN DIEGO — The sodium–glucose cotransporter 2 (SGLT2) inhibitor canagliflozin (Invokana, Janssen Pharmaceuticals) reduces cardiovascular events by 14% and cuts the rate of renal decline by 40% but also doubles the risk for lower-limb amputation, new cardiovascular-outcomes trial data indicate.
 
Combined
...
Uppgifter
Träffar: 2422

Uppgifter
Kategori: Nyheter
Studien CANagliflozin cardioVascular Assessment Study (CANVAS) har idag just presenterats på American Diabetes Association (ADA) mötet.
 
Det är en stor randomiserad studie som testade två doser av canagliflozin, SGLT2-hämmare, mot placebo hos patienter med typ 2 diabetes, både med och utan tidigare
...
Uppgifter
Träffar: 2352

Uppgifter
Kategori: Nyheter
Tresiba® demonstrated no increased risk of major cardiovascular events and significant reduction in rates of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial
 
San Diego, US, 12 June 2017 ­- Novo Nordisk today announced the primary results from DEVOTE - the first
...
Uppgifter
Träffar: 4058

Uppgifter
Kategori: Nyheter
Carla J Greenbaum, USA
Delaying T1DM is important. It means a longer period of time without the day to day extra job or living with T1DM.
 
This is the largest trial ever performed using oral insulin. Oral insulin did not delay clinical diagnosis of T1DM in the main strata of 389 peiple, or when all the
...
Uppgifter
Träffar: 2385

Uppgifter
Kategori: Nyheter
SAN DIEGO — The recent results of large outcomes trials showing cardiovascular benefit with type 2 diabetes drugs must be properly incorporated into treatment guidelines, such as those issued by the American Diabetes Association and other national guidelines all over the world, implores one
...
Uppgifter
Träffar: 2263

Uppgifter
Kategori: Nyheter

SAN DIEGO — Use of metformin may offer some atherosclerosis protection for patients with type 1 diabetes but does not appear to improve glycemic control, new data suggest.

Findings from the double-blind, placebo-controlled Reducing with Metformin Vascular Adverse Lesions (REMOVAL) trial were

...
Uppgifter
Träffar: 2254

Uppgifter
Kategori: Nyheter
SAN DIEGO — Treatment options for sexual dysfunction in diabetic patients are surprisingly limited, and new therapeutic targets are needed for both sexes, according to new data presented here at the American Diabetes Association (ADA) 2017 Scientific Sessions.
 
To enable this, more information on
...
Uppgifter
Träffar: 2093

Uppgifter
Kategori: Nyheter
Those two words were woven through a Sunday morning address by Alvin C. Powers, MD, ADA President, Medicine & Science.
 
Today’s researchers and clinicians work in a 140-character, 24-hour news cycle, understanding that messaging is critical when trying to get the public’s attention, gain notice
...
Uppgifter
Träffar: 2298

Uppgifter
Kategori: Nyheter
SAN DIEGO — Meeting attendees are pushing back against the enforcement of severe restrictions on social media posts that discuss the American Diabetes Association (ADA) 2017 Scientific Sessionstaking place here this week.
 
Since the meeting began on Friday, June 9, many of the attendees' Twitter
...
Uppgifter
Träffar: 2320

Uppgifter
Kategori: Nyheter
SAN DIEGO — In a large Danish, longitudinal population-based study, boys who were overweight as children but who had returned to normal weight by age 18 did not have an increased risk of type 2 diabetes compared with those age 18 who had never been overweight in childhood.
 
"These findings suggest
...
Uppgifter
Träffar: 2155

Uppgifter
Kategori: Nyheter

SAN DIEGO — First data on use of a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor specifically in patients with diabetes failed to excite here at the American Diabetes Association (ADA) 2017 Scientific Sessions .

Alirocumab (Praluent, Sanofi/Regeneron Pharmaceuticals) met its primary efficacy end

...
Uppgifter
Träffar: 2533

Uppgifter
Kategori: Nyheter
Outstanding Educator in Diabetes Award recipient trumpets value of team-based care
Posted By: ADA Dailyon: June 11, 2017In: 2017, ADA Daily, All, Sunday
Print Email
Share0
Tweet
Share0
Share0
Share0
Davida F. Kruger, MSN, APRN-BC, BC-ADM
The Diabetes Control and Complications Trial (DCCT) did more than confirm
...
Uppgifter
Träffar: 2425

Uppgifter
Kategori: Nyheter
The Diabetes Prevention Program (DPP) started in 1996, but its benefits continue to improve the lives of those with diabetes and prediabetes, according to Brenda Montgomery, RN, MSHS, CDE, ADA President, Health Care & Education.
 
T2DM Can And Should Be Prevented 2017
 
During her presidential address
...
Uppgifter
Träffar: 1983

Uppgifter
Kategori: Nyheter
Fans of diabetes clinical trials rejoice: The American Diabetes Association (ADA) 2017 Scientific Sessions is your meeting.
 
Of course, the annual ADA conference always offers cutting-edge research on just about every aspect of diabetes for scientists, clinicians, other professionals, patients, and
...
Uppgifter
Träffar: 2204

Uppgifter
Kategori: Nyheter
NEW ORLEANS — New data from the EMPA-REG OUTCOME trial with the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin (Jardiance, Boehringer Ingelheim) show that the drug significantly reduced the incidence of worsening nephropathy by 39% in the population of type 2 diabetes patients studied
...
Uppgifter
Träffar: 2366

Uppgifter
Kategori: Nyheter
NEW ORLEANS — Nearly closed-loop systems (also referred to as an "artificial pancreas") for improving glycemic control and minimizing hypoglycemia in type 1 diabetes are advancing rapidly, including iterations that deliver insulin alone, insulin with glucagon, or glucagon alone.
 
Findings for
...
Uppgifter
Träffar: 2580

Uppgifter
Kategori: Nyheter
NEW ORLEANS — Details of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results—A Long Term Evaluation (LEADER) trial of the glucose-lowering drug liraglutide (Victoza, Novo Nordisk), showing that it significantly reduced the rates of major adverse
...
Uppgifter
Träffar: 2379

Uppgifter
Kategori: Nyheter
SAN DIEGO — A talk on whether sulfonylureas still have a role in the contemporary treatment of type 2 diabetes
garnered much interest here at the American Diabetes Association (ADA) 2017 Scientific Sessions.
 
Speaking to a large audience in a packed room, Kamlesh Khunti, MD, from the University of
...
Uppgifter
Träffar: 2272

Uppgifter
Kategori: Nyheter

SAN DIEGO — New data from the Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN-6), a 1 weekly given GLP-analog,  provide a plausible explanation for the worsening retinopathy seen among patients taking the investigational

...
Uppgifter
Träffar: 1907

Uppgifter
Kategori: Nyheter

SAN DIEGO — New data from the Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN-6), a 1 weekly given GLP-analog,  provide a plausible explanation for the worsening retinopathy seen among patients taking the investigational

...
Uppgifter
Träffar: 2307

Uppgifter
Kategori: Nyheter
The risk of developing diabetic ketoacidosis (DKA) among type 2 diabetes patients initiating a sodium–glucose cotransporter 2 (SGLT2) inhibitor medication is about double that seen among patients starting a dipeptidyl peptidase-4 (DPP-4) inhibitor, but the overall risk is still low, new research
...
Uppgifter
Träffar: 2903